What is the 13F Pro Quality Score for AUPH?

13F Pro ranks Aurinia Pharmaceuticals Inc. (AUPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AUPH's current score at https://13fpro.ai/company/AUPH (free sign-up required for the full ranking).

Which hedge funds own the most AUPH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AUPH include TANG CAPITAL MANAGEMENT, BlackRock,, GOLDMAN SACHS GROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AUPH as soon as new 13F filings post.

Where does 13F Pro source AUPH data?

All Aurinia Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Aurinia Pharmaceuticals Inc. files with the SEC under CIK 1600620. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AUPH in?

Aurinia Pharmaceuticals Inc. (AUPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives AUPH's revenue?

Per Aurinia Pharmaceuticals Inc.'s latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Net product sales (LUPKYNIS) ($79.4M, +19% YoY); License, collaboration and royalty revenue ($3.8M, +12% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/AUPH.

What are AUPH's largest expenses?

Aurinia Pharmaceuticals Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($23.5M, -$2.5M YoY); Research and development ($13.1M, +$5.6M YoY); Cost of revenue ($6.6M, -7% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is AUPH research updated on 13F Pro?

AUPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aurinia Pharmaceuticals Inc.(AUPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1600620 AUPH stock profile & AI dashboard →

13F Pro Quality Score

75.2/100

Rank #101 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

82.5/100

Profitability

99.4/100

Balance Sheet

99.4/100

Earnings Quality

56.4/100

Free Cash Flow

96.5/100

Institutional Flow

68.5/100

Revenue Scale

30.1/100

Dilution Risk

24.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AUPH Scores 75/100

exact factor attribution · 2026-09-11

AUPH's composite is driven by profitability and free cash flow, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.4 pts

99th pct

Free cash flow

+7.0 pts

97th pct

Revenue growth

+6.5 pts

83th pct

Capital efficiency

+4.9 pts

99th pct

Earnings growth

+2.1 pts

92th pct

Institutional flow

+0.9 pts

69th pct

Earnings quality

+0.6 pts

56th pct

Shareholder dilution

-1.3 pts

24th pct

Scale

-3.0 pts

30th pct

Latest change (2026-08-06): 73 → 70 · ↓ Revenue growth 85→69

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AUPH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Aurinia Pharmaceuticals Inc. (AUPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUPH at 75.2/100 on a 32-signal composite quality model, placing it at rank #101 of 2,961 stocks — the top 5% of the AI-ranked universe. AUPH scores in the top quartile across profitability (99.4), balance sheet strength (99.4), free cash flow (96.5). Areas of concern include revenue scale (30.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Aurinia Pharmaceuticals Inc. reports quarterly revenue of $83.2M, net income of $37.4M. Top institutional holders of AUPH by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock, GOLDMAN SACHS GROUP, based on the most recent SEC filings. AUPH trades on the Nasdaq exchange and files with the SEC under CIK 1600620. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aurinia Pharmaceuticals Inc. directly from SEC EDGAR. Aurinia Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 28 and 75 since 2021, currently 75.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Aurinia Pharmaceuticals Inc.

Quirks, history, and lore behind AUPH — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in British Columbia.
2
The Numbers
Revenue in the tens of millions of dollars annually, funded heavily by its first commercial product — the kind of revenue profile that keeps biotech investors nervously refreshing their brokerage apps.
3
The History
The company spent years in clinical development before winning FDA approval in 2021 for its lead drug — a milestone that turned a research-stage company into a commercial one almost overnight.
4
The Secret
Its entire commercial bet is on a single oral drug targeting lupus nephritis, a serious autoimmune kidney disease with very few approved treatment options.
5
The Lore
The approved drug, voclosporin, works by inhibiting calcineurin — a mechanism borrowed from transplant medicine and retuned specifically for lupus kidney inflammation.
6
The Giveaway
One drug, one disease, one very niche corner of nephrology: their flagship product Lupkynis is the first oral calcineurin inhibitor ever approved specifically for lupus nephritis.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving AUPH's Business? Latest 10-Q Breakdown

✓ 19/19 datapoints verified

AI-extracted from Aurinia Pharmaceuticals Inc.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose to $83.2M on LUPKYNIS net product sales of $79.4M (+19% YoY), with net income of $37.4M after income tax expense jumped to $11.4M.

Biggest Revenue Drivers

Net product sales (LUPKYNIS)$79.4M+19% YoY

Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration

License, collaboration and royalty revenue$3.8M+12% YoY

Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant

Biggest Revenue Drivers

Total revenue: $83.2M

Net product sales (LUPKYNIS)$79.4M+19% YoY

Increase in LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration

License, collaboration and royalty revenue$3.8M+12% YoY

Primarily manufacturing services provided to Otsuka for sharing capacity of the Monoplant

Largest Expense Items

Selling, general and administrative$23.5M-$2.5M YoY

Lower share-based compensation tied to March 2026 officer departures and reversals from forfeited unvested awards

Research and development$13.1M+$5.6M YoY

Higher employee-related costs supporting development activities and increased clinical supply and distribution

Cost of revenue$6.6M-7% YoY

Decrease in sales of LUPKYNIS inventory to Otsuka, which has a low gross margin

Other (income) expense, net$(6.2)Mvs $9.2M expense YoY

Favorable foreign exchange remeasurement of the Swiss Franc-denominated Monoplant finance lease liability and settlement of a former officer obligation

Margins: Gross margin was 92% for the quarter versus 90% a year earlier, as lower-margin LUPKYNIS inventory sales to Otsuka declined. Company expects SG&A to stay consistent with 2025 and R&D to increase.

Watch Items from the Filing

Revenue depends on two specialty pharmacies, one specialty distributor and partner Otsuka — all customers for accounting purposes — plus a single commercial product, LUPKYNIS.
Income tax expense rose to $11.4M from $0.6M; effective rate 23.3% versus 2.9%, as the 2025 valuation allowance release left no unrecognized deferred tax assets to offset tax.
Kezar acquisition closed May 11, 2026 for $55.5M total consideration, treated as an asset acquisition; $3.7M contingent value right liability recorded plus $23.1M deferred tax benefits.
Monoplant finance lease requires a quarterly fixed fee of CHF 3.6 million through March 31, 2030; lease liability stands at $60.4M with FX remeasurement swinging other income.
Repurchased 2.5M shares for $38.1M in the quarter ($213.4M program-to-date); $86.6M remains authorized, with no buybacks in June 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$83.2M

Net Income

Q2 2026

$37.4M

ROIC

Q2 2026

30.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.4% YoY

$283.1MFY 2025

FY22 $134.0MFY23 $175.5MFY24 $235.1MFY25 $283.1M

Net Income

+4893.1% YoY

$287.2MFY 2025

FY22 $-108.2MFY23 $-78.0MFY24 $5.8MFY25 $287.2M

Operating Income

+2338.4% YoY

$104.9MFY 2025

FY22 $-111.5MFY23 $-91.7MFY24 $-4.7MFY25 $104.9M

EPS (Diluted)

+5075.0% YoY

$2.07FY 2025

FY22 $-0.76FY23 $-0.54FY24 $0.04FY25 $2.07

Total Assets

+36.5% YoY

$751.6MFY 2025

FY22 $470.9MFY23 $548.1MFY24 $550.6MFY25 $751.6M

Op. Cash Flow

+205.6% YoY

$135.7MFY 2025

FY22 $-79.5MFY23 $-33.5MFY24 $44.4MFY25 $135.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$283.1M +20.4%	$235.1M +34.0%	$175.5M +31.0%	$134.0M +193.9%	$45.6M -9.0%	$50.1M
Net Income	$287.2M +4893.1%	$5.8M +107.4%	$-78.0M +27.9%	$-108.2M +40.2%	$-181.0M -76.2%	$-102.7M
Operating Income	$104.9M +2338.4%	$-4.7M +94.9%	$-91.7M +17.7%	$-111.5M +38.3%	$-180.7M -73.3%	$-104.3M
EPS (Diluted)	$2.07 +5075.0%	$0.04 +107.4%	$-0.54 +28.9%	$-0.76 +45.7%	$-1.40 -60.9%	$-0.87
Total Assets	$751.6M +36.5%	$550.6M +0.5%	$548.1M +16.4%	$470.9M -13.3%	$543.4M +17.2%	$463.7M
Operating Cash Flow	$135.7M +205.6%	$44.4M +232.7%	$-33.5M +57.9%	$-79.5M +49.6%	$-157.7M -125.7%	$-69.9M

Get alerted when AUPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aurinia Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AUPH

TANG CAPITAL MANAGEMENT LLC
$221.4M13,044,106 sh
BlackRock, Inc.
$139.0M8,193,085 sh
GOLDMAN SACHS GROUP INC
$95.4M5,619,401 sh
NEA Management Company, LLC
$67.4M3,969,834 sh
TWO SIGMA INVESTMENTS, LP
$58.8M3,467,514 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$55.4M3,264,062 sh
STATE STREET CORP
$43.9M2,589,615 sh
MORGAN STANLEY
$39.2M2,308,244 sh
MARSHALL WACE, LLP
$34.7M2,044,007 sh
GEODE CAPITAL MANAGEMENT, LLC
$28.9M1,701,152 sh

Fund	Value	Shares
TANG CAPITAL MANAGEMENT LLC	$221.4M	13,044,106
BlackRock, Inc.	$139.0M	8,193,085
GOLDMAN SACHS GROUP INC	$95.4M	5,619,401
NEA Management Company, LLC	$67.4M	3,969,834
TWO SIGMA INVESTMENTS, LP	$58.8M	3,467,514
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$55.4M	3,264,062
STATE STREET CORP	$43.9M	2,589,615
MORGAN STANLEY	$39.2M	2,308,244
MARSHALL WACE, LLP	$34.7M	2,044,007
GEODE CAPITAL MANAGEMENT, LLC	$28.9M	1,701,152

Companies Similar to AUPH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CRMD

CorMedix Inc.

AI score

Similar quality profile · 8 shared holders

Headlands Technologies LLC AVIVA PLC Freestone Grove Partners LP

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 17 shared holders

TANG CAPITAL MANAGEMENT LLC PDT Partners, LLC SEGALL BRYANT & HAMILL, LLC

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile · 7 shared holders

EntryPoint Capital, LLC AVIVA PLC Diametric Capital, LP

TBPH

Theravance Biopharma, Inc.

AI score

Similar quality profile · 12 shared holders

CWA Asset Management Group, LLC MARTINGALE ASSET MANAGEMENT L P Virtus Investment Advisers, LLC

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 9 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC LSV ASSET MANAGEMENT JUPITER ASSET MANAGEMENT LTD

LQDA

Liquidia Corp

AI score

Similar quality profile · 12 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC SEGALL BRYANT & HAMILL, LLC Virtus Investment Advisers, LLC

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 8 shared holders

NAVELLIER & ASSOCIATES INC JUNCTURE WEALTH STRATEGIES, LLC PDT Partners, LLC

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 19 shared holders

TANG CAPITAL MANAGEMENT LLC RICE HALL JAMES & ASSOCIATES, LLC NORDEA INVESTMENT MANAGEMENT AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AUPH on your watchlist

Track score changes the day Aurinia Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AUPH a good stock to buy?

13F Pro's AI-powered analysis of Aurinia Pharmaceuticals Inc. (AUPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AUPH are available on the AUPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AUPH is classified as a mid company.

Which hedge funds own AUPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AUPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aurinia Pharmaceuticals Inc.'s investment landscape.